Belinda Nedjai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1778391/publications.pdf

Version: 2024-02-01

567281 2,142 23 15 citations h-index papers

g-index 24 24 24 4326 docs citations times ranked citing authors all docs

610901

24

#	Article	IF	CITATIONS
1	Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: A worldwide study. International Journal of Cancer, 2022, 150, 290-302.	5.1	18
2	<scp>DNA</scp> methylation testing with <scp>S5</scp> for triage of highâ€risk <scp>HPV</scp> positive women. International Journal of Cancer, 2022, 151, 993-1004.	5.1	8
3	Methylation of <scp>HPV16</scp> and <i>EPB41L3</i> in oral gargles and the detection of early and late oropharyngeal cancer. Cancer Medicine, 2022, 11, 3735-3742.	2.8	1
4	Effective methylation triage of <scp>HPV</scp> positive women with abnormal cytology in a middleâ€income country. International Journal of Cancer, 2021, 148, 1383-1393.	5.1	21
5	A Randomized Comparison of Different Vaginal Self-sampling Devices and Urine for Human Papillomavirus Testingâ€"Predictors 5.1. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 661-668.	2.5	38
6	Consistency of the S5 DNA methylation classifier in formalinâ€fixed biopsies versus corresponding exfoliated cells for the detection of preâ€cancerous cervical lesions. Cancer Medicine, 2021, 10, 2668-2679.	2.8	3
7	Rationale and design of the Prevent Anal Cancer Self-Swab Study: a protocol for a randomised clinical trial of home-based self-collection of cells for anal cancer screening. BMJ Open, 2021, 11, e051118.	1.9	8
8	Performance of an affordable urine self-sampling method for human papillomavirus detection in Mexican women. PLoS ONE, 2021, 16, e0254946.	2. 5	10
9	Methylation of HPV 16 and <i>EPB41L3</i> in oral gargles: Associations with oropharyngeal cancer detection and tumor characteristics. International Journal of Cancer, 2020, 146, 1018-1030.	5.1	18
10	Methylation in Predicting Progression of Untreated High-grade Cervical Intraepithelial Neoplasia. Clinical Infectious Diseases, 2020, 70, 2582-2590.	5.8	45
11	Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping. Clinical Epigenetics, 2019, 11, 140.	4.1	27
12	Human Papillomavirus Research: Where Should We Place Our Bets?. Acta Cytologica, 2019, 63, 85-96.	1.3	5
13	Molecular progression to cervical precancer, epigenetic switch or sequential model?. International Journal of Cancer, 2018, 143, 1720-1730.	5.1	21
14	Glucolipotoxicity initiates pancreatic \hat{l}^2 -cell death through TNFR5/CD40-mediated STAT1 and NF- \hat{l}^2 B activation. Cell Death and Disease, 2016, 7, e2329-e2329.	6.3	34
15	CXCR 3 antagonist VUF 10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK â€₹79. British Journal of Pharmacology, 2015, 172, 1822-1833.	5.4	13
16	Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 2563-2582.	4.1	1,514
17	Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion. Bioscience Reports, 2012, 32, 105-112.	2.4	39
18	Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3. British Journal of Pharmacology, 2012, 166, 912-923.	5 . 4	38

#	Article	lF	CITATIONS
19	Differential cytokine secretion results from p65 and c-Rel NF-κB subunit signaling in peripheral blood mononuclear cells of TNF receptor-associated periodic syndrome patients. Cellular Immunology, 2011, 268, 55-59.	3.0	24
20	Lessons from Anti-TNF Biologics: Infliximab Failure in a TRAPS Family with the T50M Mutation in TNFRSF1A. Advances in Experimental Medicine and Biology, 2011, 691, 409-419.	1.6	19
21	Elucidation of Binding Sites of Dual Antagonists in the Human Chemokine Receptors CCR2 and CCR5. Molecular Pharmacology, 2009, 75, 1325-1336.	2.3	52
22	Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor–associated periodic syndrome. Arthritis and Rheumatism, 2009, 60, 619-625.	6.7	110
23	Abnormal tumor necrosis factor receptor I cell surface expression and NFâ€PB activation in tumor necrosis factor receptor–associated periodic syndrome. Arthritis and Rheumatism, 2008, 58, 273-283.	6.7	75